Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (LIVIGNO-4)
A Randomized, Phase 2/3 Study to Evaluate the Optimal Dose, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Sponsor: AbbVie
Listed as NCT06236438, this PHASE2/PHASE3 trial focuses on Non-Small Cell Lung Cancer and remains actively recruiting participants. Sponsored by AbbVie, it has been updated 21 times since 2024, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
21 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE2/PHASE3
-
Dec 2025 — Feb 2026 [monthly]
Recruiting PHASE2/PHASE3
-
Sep 2025 — Dec 2025 [monthly]
Recruiting PHASE2/PHASE3
-
Aug 2025 — Sep 2025 [monthly]
Recruiting PHASE2/PHASE3
-
Jul 2025 — Aug 2025 [monthly]
Recruiting PHASE2/PHASE3
▶ Show 16 earlier versions
-
Jun 2025 — Jul 2025 [monthly]
Recruiting PHASE2/PHASE3
-
May 2025 — Jun 2025 [monthly]
Recruiting PHASE2/PHASE3
-
Apr 2025 — May 2025 [monthly]
Recruiting PHASE2/PHASE3
-
Mar 2025 — Apr 2025 [monthly]
Recruiting PHASE2/PHASE3
-
Feb 2025 — Mar 2025 [monthly]
Recruiting PHASE2/PHASE3
-
Jan 2025 — Feb 2025 [monthly]
Recruiting PHASE2/PHASE3
-
Dec 2024 — Jan 2025 [monthly]
Recruiting PHASE2/PHASE3
-
Nov 2024 — Dec 2024 [monthly]
Recruiting PHASE2/PHASE3
-
Oct 2024 — Nov 2024 [monthly]
Recruiting PHASE2/PHASE3
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE2/PHASE3
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE2/PHASE3
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE2_PHASE3
-
May 2024 — Jun 2024 [monthly]
Recruiting PHASE2_PHASE3
-
Apr 2024 — May 2024 [monthly]
Recruiting PHASE2_PHASE3
Status: Not Yet Recruiting → Recruiting
-
Mar 2024 — Apr 2024 [monthly]
Not Yet Recruiting PHASE2_PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- AbbVie
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ankara, Turkey (Türkiye) , Athens, United States , Barcelona, Spain , Bron, France , Brussels, Belgium , Chicago, United States , Chuo-ku, Japan , Cincinnati, United States , Créteil, France , Edegem, Belgium and 47 more locations